Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
Stocks · News reference
Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its Patent Application Entitled Compositions And Methods Of Use
Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Xeris Biopharma shares are trading lower after the company reported mixed Q2 financial results.
UPDATE: Xeris Biopharma Holdings Q2 Adj. EPS $0.00, Inline
8-K filing — Xeris Biopharma Holdings, Inc. (XERS)
Filed: 2026-08-06 AccNo: 0001867096-26-000063 Size: 334 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits